Evidence map›Paper›PMID 24793657›Full record

ArticleActa biomaterialia2014

Porous silicon oxide-PLGA composite microspheres for sustained ocular delivery of daunorubicin.

Kaihui Nan, Feiyan Ma, Huiyuan Hou, William R Freeman, Michael J Sailor, Lingyun Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta biomaterialia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kaihui NanDepartment of Ophthalmology, Jacobs Retina Center/Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA; Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China.
Feiyan MaDepartment of Ophthalmology, Jacobs Retina Center/Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA.
Huiyuan HouDepartment of Ophthalmology, Jacobs Retina Center/Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA.
William R FreemanDepartment of Ophthalmology, Jacobs Retina Center/Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA.
Michael J SailorDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA, USA.
Lingyun ChengDepartment of Ophthalmology, Jacobs Retina Center/Shiley Eye Center, University of California, San Diego, La Jolla, CA, USA. Electronic address: cheng@eyecenter.ucsd.edu.

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2012 to 2026
$10.3M
Porous Silicon Particles for Sustained Intravitreal Drug DeliveryR01EY020617 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CHENG, LINGYUN · 2011 to 2015
$2.6M
NEI NIH HHS EY020617NEI NIH HHS P30 EY022589NEI NIH HHS P30EY022589NEI NIH HHS R01 EY020617
6 · The paper itself

Abstract

A water-soluble anthracycline antibiotic drug (daunorubicin, DNR) was loaded into oxidized porous silicon (pSiO2) microparticles and then encapsulated with a layer of polymer (poly lactide-co-glycolide, PLGA) to investigate their synergistic effects in control of DNR release. Similarly fabricated PLGA-DNR microspheres without pSiO2, and pSiO2 microparticles without PLGA were used as control particles. The composite microparticles synthesized by a solid-in-oil-in-water emulsion method have mean diameters of 52.33±16.37μm for PLGA-pSiO2_21/40-DNR and the mean diameter of 49.31±8.87μm for PLGA-pSiO2_6/20-DNR. The mean size, 26.00±8μm, of PLGA-DNR was significantly smaller, compared with the other two (P<0.0001). Optical microscopy revealed that PLGA-pSiO2-DNR microspheres contained multiple pSiO2 particles. In vitro release experiments determined that control PLGA-DNR microspheres completely released DNR within 38days and control pSiO2-DNR microparticles (with no PLGA coating) released DNR within 14days, while the PLGA-pSiO2-DNR microspheres released DNR for 74days. Temporal release profiles of DNR from PLGA-pSiO2 composite particles indicated that both PLGA and pSiO2 contribute to the sustained release of the payload. The PLGA-pSiO2 composite displayed a more constant rate of DNR release than the pSiO2 control formulation, and displayed a significantly slower release of DNR than either the PLGA or pSiO2 formulations. We conclude that this system may be useful in managing unwanted ocular proliferation when formulated with antiproliferation compounds such as DNR.

Indexed as

Absorption, PhysicochemicalAdministration, OphthalmicAdsorptionAnti-Bacterial AgentsCapsulesDaunorubicinDelayed-Action PreparationsDiffusionLactic AcidMaterials TestingPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerPorositySilicon DioxideAnti-Bacterial AgentsCapsulesDaunorubicinDelayed-Action PreparationsLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid CopolymerSilicon DioxideDaunorubicinOcular drug deliveryPoly(dl-lactide-co-glycolide)Porous silicon oxide

Identifiers

PMID24793657
PMCPMC4106702

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.